NASDAQ:VRTX Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis $514.65 +12.70 (+2.53%) Closing price 10/20/2026 04:00 PM EasternExtended Trading$508.97 -5.68 (-1.10%) As of 05:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vertex Pharmaceuticals Stock (NASDAQ:VRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vertex Pharmaceuticals alerts:Sign Up Key Stats Today's Range$505.00▼$515.7450-Day Range$485.22▼$557.9652-Week Range$403.16▼$560.25Volume1.23 million shsAverage Volume1.19 million shsMarket Capitalization$130.62 billionP/E Ratio29.96Dividend YieldN/APrice Target$579.81Consensus RatingModerate Buy Company Overview Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs. Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene. The company also markets Casgevy, a gene-editing therapy developed in collaboration with CRISPR Therapeutics for sickle cell disease and transfusion-dependent beta thalassemia. In addition to its cystic fibrosis and genetic-disease programs, Vertex develops treatments in areas including acute and chronic pain, kidney disease, and type 1 diabetes. Its non-opioid pain medicine, Journavx (suzetrigine), is designed to treat moderate to severe acute pain. Vertex serves patients and healthcare providers in the United States and international markets through its commercial operations and global research and development activities. Reshma Kewalramani has served as Vertex’s president and chief executive officer since 2017. The company continues to invest in research aimed at developing medicines that address the underlying biology of disease rather than primarily managing symptoms.AI Generated. May Contain Errors. Read More Vertex Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreVRTX MarketRank™: 4.020342612415 of 5 starsVertex Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat, and ranked 127th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingVertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 1 strong buy rating, 24 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialVertex Pharmaceuticals has a consensus price target of $579.81, representing about 12.7% upside from its current price of $514.65.Amount of Analyst CoverageVertex Pharmaceuticals has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vertex Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth10.15% Earnings GrowthEarnings for Vertex Pharmaceuticals are expected to grow by 10.15% in the coming year, from $16.75 to $18.45 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vertex Pharmaceuticals is 29.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 35.83.Price to Earnings Ratio vs. SectorThe P/E ratio of Vertex Pharmaceuticals is 29.96, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 207.60.Price to Earnings Growth RatioVertex Pharmaceuticals has a PEG Ratio of 2.41. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioVertex Pharmaceuticals has a P/B Ratio of 7.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vertex Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.78% of the float of Vertex Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVertex Pharmaceuticals has a short interest ratio ("days to cover") of 4.24.Change versus previous monthShort interest in Vertex Pharmaceuticals has recently decreased by 4.53%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVertex Pharmaceuticals does not currently pay a dividend.Dividend GrowthVertex Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment0.63 News SentimentVertex Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Vertex Pharmaceuticals this week, compared to 8 articles on an average week.Search Interest29 people have searched for VRTX on MarketBeat in the last 30 days. This is an increase of 4% compared to the previous 30 days.MarketBeat Follows37 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 208% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vertex Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.20% of the stock of Vertex Pharmaceuticals is held by insiders.Percentage Held by Institutions90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vertex Pharmaceuticals' insider trading history. Receive VRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRTX Stock News HeadlinesAbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?October 20 at 5:15 PM | fool.comVertex Appoints Daniel Brennan to its Board of DirectorsOctober 20 at 4:05 PM | businesswire.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | Stansberry Research (Ad)Vertex Pharmaceuticals (VRTX) Sees $11.6 Million in Net ETF Buying on ThursdayOctober 19 at 8:17 AM | finance.yahoo.comWhat Vertex Pharmaceuticals (VRTX)'s Pancreas Recovery Data Means For ShareholdersOctober 18 at 2:09 PM | finance.yahoo.comVertex Pharmaceuticals (NASDAQ:VRTX) Stock Moved Up to Buy by Wall Street ZenOctober 17, 2026 | americanbankingnews.comIs Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?October 16, 2026 | finance.yahoo.comVertex Pharmaceuticals, Inc.October 15, 2026 | money.usnews.comSee More Headlines VRTX Stock Analysis - Frequently Asked Questions How have VRTX shares performed this year? Vertex Pharmaceuticals' stock was trading at $453.36 at the beginning of the year. Since then, VRTX shares have increased by 13.5% and is now trading at $514.65. How were Vertex Pharmaceuticals' earnings last quarter? Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its quarterly earnings data on Monday, August, 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.74 by $0.01. The company's quarterly revenue was up 12.5% compared to the same quarter last year. Read the conference call transcript. Does Vertex Pharmaceuticals have any subsidiaries? Vertex Pharmaceuticals subsidiaries include these companies: V2X, Semma Therapeutics, Exonics Therapeutics, Aurora Biosciences Corporation, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, and more. Who are Vertex Pharmaceuticals' major shareholders? Vertex Pharmaceuticals' top institutional investors include Robeco Institutional Asset Management B.V. (0.17%), AMI Asset Management Corp (0.03%), Sumitomo Mitsui DS Asset Management Company Ltd (0.02%) and Nisa Investment Advisors LLC (0.02%). Insiders that own company stock include Reshma Kewalramani, Stuart A Arbuckle, Amit Sachdev, Ourania Tatsis, Bruce I Sachs, Charles F Wagner Jr, Jeffrey M Leiden, David Altshuler, Joy Liu, Edward Morrow Atkinson III, Carmen Bozic, Jonathan Biller, Duncan Mckechnie, Mark E Bunnage, Kristen Ambrose and Sangeeta N Bhatia. View institutional ownership trends. How do I buy shares of Vertex Pharmaceuticals? Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vertex Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Salesforce (CRM), Alibaba Group (BABA), Micron Technology (MU) and Netflix (NFLX). Company Calendar Last Earnings8/03/2026Today10/20/2026American Society of Nephrology (ASN) Kidney Week 202610/23/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 7 days, VRTX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VRTX CIK875320 Webwww.vrtx.com Phone(617) 341-6100Fax617-576-2109Employees6,400Year Founded1989Price Target and Rating Average Price Target for Vertex Pharmaceuticals$579.81 High Price Target$665.00 Low Price Target$442.00 Potential Upside/Downside+12.7%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage28 Analysts Profitability EPS (Trailing Twelve Months)$17.18 Trailing P/E Ratio29.96 Forward P/E Ratio30.73 P/E Growth2.41Net Income$3.95 billion Net Margins35.00% Pretax Margin41.90% Return on Equity23.09% Return on Assets16.72% Debt Debt-to-Equity RatioN/A Current Ratio3.19 Quick Ratio2.74 Sales & Book Value Annual Sales$12.00 billion Price / Sales10.88 Cash Flow$18.02 per share Price / Cash Flow28.56 Book Value$73.57 per share Price / Book7.00Miscellaneous Outstanding Shares253,800,000Free Float253,297,000Market Cap$130.62 billion OptionableOptionable Beta0.28 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:VRTX) was last updated on 10/20/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
